Illumina Announces Winners of MiSeq® Grant Program
News Nov 08, 2012
Illumina, Inc. has announced the winners of its MiSeq grant program at the American Society of Human Genetics (ASHG) annual meeting in San Francisco.
Illumina received almost 850 applications from researchers in over 40 countries in fields as diverse as microbiology, cancer, inherited disease, and evolutionary biology.
The awardees are:
• Ramunas Stepanauskas, from the Bigelow Laboratory for Ocean Sciences, East Boothbay, Maine, for sequencing single cells from unculturable strains of bacteria in the dark ocean;
• Stephen Doyle, from La Trobe University, Melbourne, Australia, for investigating drug resistance in the causative agent of African river blindness; and
• Karin Haack, from the Texas Biomedical Research Institute, San Antonio, Texas, for targeted resequencing of genes implicated in cardiovascular disease.
"We are excited to broaden access to MiSeq and engage with researchers who are developing novel applications with Illumina technology," said Gary Schroth, Distinguished Scientist at Illumina.
Schroth continued, "The grant applications we received showed an incredible range of creativity. We look forward to working with the grant recipients as they make discoveries, innovate, and accelerate the research being done in their areas of expertise."
The MiSeq grant program was developed to enable any researcher - from novices to current Illumina customers anywhere in the world - to gain access to next generation sequencing (NGS) to further their research, as well as to advance innovation in applications that can only be enabled by NGS capabilities.
Entries were judged by a team of scientific reviewers from Illumina and evaluated based upon scientific merit, originality, and applicability to the unique capabilities of the MiSeq system.
Each of the three winners will receive a MiSeq, sample preparation and sequencing reagent kits, data analysis software and storage, training, and technical support valued at more than $150,000 per prize.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE